← Back to Search

Vitamin E

Tocotrienol for Pancreatic Tumors

Phase 2
Recruiting
Led By Mokenge P Malafa, MD, FACS
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, month 6, 12, 24 and 36

Summary

This trial is testing if a medication called δ-tocotrienol can stop the growth of a certain type of pancreatic tumor called Intraductal Papillary Mucinous Neoplasm (IP

Who is the study for?
This trial is for individuals with a condition called IPMN, which can lead to pancreatic cancer. Participants should not have received prior treatment for this condition and must be in stable health otherwise.
What is being tested?
The study is testing if taking a form of Vitamin E known as Delta-tocotrienol (DT3) can stop IPMN from getting worse. It's a blind test, so neither the doctors nor patients know who gets DT3 or a placebo.
What are the potential side effects?
While specific side effects are not listed here, common ones associated with vitamin E supplements may include fatigue, headache, blurred vision, rash, bruising or bleeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, month 6, 12, 24 and 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, month 6, 12, 24 and 36 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
IPMN Progression Free Survival (iPFS)
Secondary study objectives
Acceptability of DT3 Treatment
Adherence of DT3 Treatment
Bioavailability and Biodistribution
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Vitamin E Delta-tocotrienol (DT3)Experimental Treatment1 Intervention
Patients will be given DT3 orally (by mouth) twice daily for 3 years
Group II: PlaceboActive Control1 Intervention
Patients will be given a placebo (a substance that looks like the study drug, but contains not active ingredients) orally (by mouth) twice daily for 3 years

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
561 Previous Clinical Trials
144,617 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,917 Previous Clinical Trials
41,014,253 Total Patients Enrolled
American River Nutrition, LLCUNKNOWN
~141 spots leftby Jul 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top